BXQ-350

Phase 1Small molecule

BBexion Pharmaceuticals, Inc.

BXQ-350 is one of 84 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Diffuse Intrinsic Pontine GliomaActive, not recruiting

Colorectal CarcinomaPhase 1/Phase 2

Active, not recruiting

Diffuse Intrinsic Pontine GliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

Sutent

Pfizer

Phase 3

1 3

Iressa

AstraZeneca

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

5 5

Golytely

Vectibix

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 9

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

1 10

Camptosar

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1/2Active, not recruiting

Colorectal Carcinoma

NCT05322590

Clinical

Trials by Indication[1]

Colorectal Carcinoma1 trial

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Active, not recruiting·BBexion Pharmaceuticals, Inc.·Phase 1/2·NCT05322590·195 enrolled

Solid Tumors1 trial

A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors

Terminated·BBexion Pharmaceuticals, Inc.·Phase 1·NCT03967093·9 enrolled

Treatment1 trial

Continued Treatment for Participants Enrolled in Studies of BXQ-350

Terminated·BBexion Pharmaceuticals, Inc.·Phase 1·NCT04404569·5 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

Completed·BBexion Pharmaceuticals, Inc.·Phase 1·NCT02859857·86 enrolled

Cancer1 trial

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

Completed·BBexion Pharmaceuticals, Inc.·Phase 1·NCT05291286·21 enrolled

1 more indication

Diffuse Intrinsic Pontine Glioma1 trial

A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)

Terminated·BBexion Pharmaceuticals, Inc.·Phase 1·NCT04771897·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for BXQ-350. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BXQ-350 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BXQ-350. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bexion Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBexion Pharmaceuticals, Inc.

BXQ-350

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Colorectal Carcinoma1 trial

Solid Tumors1 trial

Treatment1 trial

Patients With Advanced Solid Tumors1 trial

Cancer1 trial

Diffuse Intrinsic Pontine Glioma1 trial

References

Drug Info

Quick Facts

Related News